Malte H. Wehmeyer

Stem Cell–Derived Culture Models of Hepatitis E Virus Infection

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Pre-clinical in vivo evaluation of orthopaedic bioabsorbable devices

Mechanisms and disease consequences of nonalcoholic fatty liver disease

Porosity of 3D biomaterial scaffolds and osteogenesis

Stem cell-derived polarized hepatocytes

Inflammation in obesity, diabetes, and related disorders

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection

EASL Recommendations on Treatment of Hepatitis C 2018

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection

Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV–Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01)

Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection

Acute Hepatitis E: Two Sides of the Same Coin

[Histologic studies of replacement of the anterior cruciate ligament with PDS-augmented patellar tendon transplants].